MRI vs TURBT for Staging New Bladder Cancer: Insights from the BladderPath Trial

Bladder-Sparing Therapy vs Radical Cystectomy: Long-Term Outcomes in BCG-Unresponsive NMIBC

Bladder-Sparing Therapy in BCG-Unresponsive NMIBC: IBCG Recommendations on Sequencing & Patient Selection

Bladder-Preserving Trimodality Therapy for High-Grade T1 Bladder Cancer: NRG/RTOG 0926 Results

NIAGARA Phase 3 Trial: Neoadjuvant Durvalumab + Chemo & Adjuvant Durvalumab in MIBC

Phase II RC48-C017: Disitamab Vedotin + Toripalimab as Neoadjuvant Therapy in HER2+ MIBC

Variant Histology in NMIBC: Impact on Upstaging & Survival After Radical Cystectomy

BCG vs Gemcitabine + Docetaxel for Treatment-Naïve Intermediate-Risk NMIBC: Comparative Study

BART Trial: Acute & Late Toxicity of Adjuvant Radiation in Bladder Cancer (Phase III RCT)

Hypofractionated Chemoradiotherapy for Bladder Preservation in MIBC: Results from ESTRO 2024

Panel Discussion: Advances in Bladder Cancer Care from ESTRO & ASTRO 2024 Clinical Abstracts

Exploring First-Line Strategies in Metastatic Urothelial Carcinoma | Insights from CheckMate 901

Pembrolizumab After Tri-Modality Therapy in Muscle-Invasive Bladder Cancer | ASTRO 2024 Insights

Neoadjuvant Chemotherapy Before Chemoradiotherapy in Muscle-Invasive Bladder Cancer | Meta-Analysis Insights

ASCO GU 2025: Neoadjuvant Durvalumab + Chemo in High-Risk Upper Tract Urothelial Carcinoma

POUT Trial Final Results: Adjuvant Chemotherapy Boosts DFS After Nephroureterectomy in UTUC

TOMBOLA Trial: ctDNA-Guided Early Post-Cystectomy Immunotherapy in Bladder Cancer Patients

Enfortumab Vedotin + Pembrolizumab: First-Line Breakthrough in Advanced Urothelial Cancer

Panel Discussion: Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Cancer

ARASENS Subgroup Analysis & Key ASCO GU 2025 Updates in Prostate Cancer Research